ATG9A Antibody (C-term)

Fluorescent image of U251 cells stained with ATG9A (C-term) antibody. U251 cells were treated with Chloroquine (50 μM, 16 h), then fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.2%, 30 min). Cells were then incubated with ATG9A (C-term) primary antibody (1:100, 2 h at room temperature). For secondary antibody, Alexa Fluor 488 conjugated donkey anti-rabbit antibody (green) was used (1:1000, 1 h). Nuclei were counterstained with Hoechst 33342 (blue) (10 μg/ml, 5 min). ATG9A immunoreactivity is localized to autophagic vacuoles in the cytoplasm of U251 cells.

Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.

Western blot analysis of anti-Autophagy APG9L1 Antibody (C-term) in A2058 and A375 cell line lysates (35 ug/lane). APG9L1 (arrow) was detected using the purified Pab.

All lanes: Anti-APG9L1 Antibody (R732) at 1:1000 dilution. Lane 1: A375 whole cell lysate. Lane 2: HepG2 whole cell lysate. Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size: 94 kDa. Blocking/Dilution buffer: 5% NFDM/TBST.